Humble hero or hidden villain? The ongoing story of aspirin's powers

September 21, 2012 by Professor Andrew Tonkin, Monash University

The humble aspirin has a remarkable history dating back to ancient Egyptian times when the bark of weeping willow (which contains salicin from which the aspirin formulation is derived) was found to have anti-inflammatory properties. And Hippocrates wrote about the medicinal uses of white willow in the fifth century BC. But this story is not over yet.

This year marks another noteworthy chapter in the history of . A variety of articles about the medicine have attracted significant attention in both the scientific and lay press. Research and news stories have reported potential benefits of aspirin beyond preventing heart attacks and stroke, and re-emphasised bleeding risks.

One academic article provided an overview of individual from seven randomised cardiovascular trials of four years or more in over 23,000 patients. It showed that death from all solid cancers was reduced overall by about 15 per cent by aspirin. The effect became significant after about five years and persisted to 20 years. Risk was unrelated to aspirin dose.

But it's important to note that two very large trials – the Women's Health Study and the Physician's Health Study – of almost 60,000 individuals followed up for 10-to-12 years were excluded because they tested alternate days rather than daily aspirin. In these trials, aspirin had no effect on cancer.

Other studies by the same researchers who published the meta-analysis showing aspirin's ability to protect against cancer also showed that the medicine had early short-term effects on and mortality and that metastatic spread (particularly of adenocarcinoma) was reduced by about 40 per cent to 50 per cent in a few years.

These observations add to previous studies suggesting aspirin may play a role in preventing , particularly in at-risk groups. We can only speculate about how this happens but platelets may be involved in by releasing growth factors and in metastatic spread by their role in the circulation.

Earlier this year, researchers published an updated meta-analysis of nine placebo-controlled trials of primary prevention for cardiovascular disease, involving over 100,000 people with an average age of 57 years. The paper attracted much more negative publicity than positive. It showed a greater number of non-trivial bleeds (30 per cent increase) than cardiovascular events prevented, mainly non-fatal heart attacks. Also, in contrast to the other papers, aspirin was found to have no effect on cancer mortality.

More recently, the bleeding risk has again been underscored by Italian research showing that the risk of major bleeds, such as intracranial haemorrhage and gastrointestinal bleeding, in real-life practice is five times more than in clinical trials.

So where does this leave practising clinicians?

In patients already diagnosed with coronary artery disease or those who've suffered a stroke, or have peripheral arterial disease, aspirin should be used with other proven secondary prevention therapies (providing bleeding risk is not considered prohibitive). In such contexts, aspirin reduces the risk of recurrent cardiovascular disease by about a quarter.

In those who are apparently healthy, cancer prevention is a very important possibility. But the evidence for taking aspirin daily as a cancer preventative is not considered sufficiently robust to warrant a population-wide recommendation for it to be used like this. The decision to do so should be made on an individual basis.

What's needed is more information for patients and doctors that can inform decision-making, particularly for the elderly and people with diabetes who don't have known cardiovascular disease. This is because both ageing and diabetes increase not only risk of heart problems and stroke but also bleeding. Increasing age and possibly diabetes also increase cancer risk.

Providing the kind of information that can help resolve this dilemma is exactly what we're hoping to do with the ASPREE study. The study involves 19,000 healthy people aged 70 and over and is designed to reliably address the net effects of aspirin. The primary endpoint of the study is healthy life years that might be impacted. It not only assesses quality of life, including cognition, but will also capture all effects of aspirin, both favourable and adverse.

Randomised trials eliminate the biases and confounding that often occur in population-based studies. The ASPREE study could have a major impact not only on the well-being of older Australians but globally. Just how much of a humble hero aspirin is, or whether it is, in fact, a villain because it causes bleeding, will hopefully soon be established.

Explore further: Even low-dose aspirin may increase risk of GI bleeding

More information: Readers can get more information about the ASPREE study online

Related Stories

Even low-dose aspirin may increase risk of GI bleeding

September 12, 2011
The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer. According to a new study in Clinical ...

Benefits of aspirin more modest than previously believed

January 16, 2012
(Medical Xpress) -- People without a history of cardiovascular disease (such as heart attack or stroke) are unlikely to benefit from a regular dose of aspirin, given the associated risk of internal bleeding. This is the finding ...

Study adds to evidence daily aspirin linked to lower cancer mortality

August 10, 2012
A large new observational study finds more evidence of an association between daily aspirin use and modestly lower cancer mortality, but suggests any reduction may be smaller than that observed in a recent analysis. The study, ...

Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes

July 5, 2011
In some cases, an apple a day may keep the doctor away, but for people with diabetes, regular, over-the-counter Aspirin may also do the job.

Report says new evidence could tip the balance in aspirin cancer prevention care

April 9, 2012
A new report by American Cancer Society scientists says new data showing aspirin's potential role in reducing the risk of cancer death bring us considerably closer to the time when cancer prevention can be included in clinical ...

Recommended for you

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

January 2, 2018
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand? Restasis, a blockbuster drug ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.